申请人:UCB PHARMA S.A.
公开号:US20160194329A1
公开(公告)日:2016-07-07
A series of pyrazolo[3,4-d]pyrimidine derivatives that are substituted at the 4-position by a diaza monocyclic, bridged bicyclic or spirocyclic moiety, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
一系列在4位点取代了含有一环氮杂原子的单环、桥环或螺环的嘧唑并[3,4-d]嘧啶衍生物,在治疗和/或预防各种人类疾病方面具有益处,包括炎症、自身免疫和肿瘤性疾病;病毒性疾病和疟疾;以及器官和细胞移植排斥反应。